Humacyte (HUMA) vs Palisade Bio (PALI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Palisade Bio (PALI) has outperformed Humacyte (HUMA) over the past year, losing 60.6% versus a loss of 63.5%. Over five years, HUMA leads with a -95.9% price change compared with -100.0% for PALI. Palisade Bio is the larger company by market cap ($150.7 million vs $123.7 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HUMA | PALI |
|---|---|---|
| Share price | $0.4454 | $0.8399 |
| Market cap | $123.73M | $150.74M |
| 1-day change | -17.90% | -9.24% |
| YTD return | -53.65% | -64.26% |
| 1-year return | -63.49% | -60.57% |
| 5-year return | -95.94% | -99.95% |
| P/E ratio (TTM) | — | 0.91 |
| EPS (TTM) | $-0.45 | $0.92 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $2.04M | $0 |
| Net income (latest FY) | $-40.83M | $-16.78M |
| Gross margin | -376.05% | — |
| Operating margin | -5306.04% | — |
| Net margin | -2003.58% | — |
| 52-week high | $1.53 | $2.86 |
| 52-week low | $0.337 | $0.8381 |
| Distance from 52-week high | -70.79% | -70.63% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +268.21% | +935.84% |
| Average volume | 5.36M | 3.19M |
| Shares outstanding | 277.80M | 179.28M |
| Employees | 184 | 14 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Humacyte
HUMA stock →Humacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 184 employees
About Palisade Bio
PALI stock →Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibrostenotic Crohn's disease.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 14 employees
HUMA vs PALI FAQ
Which is bigger, Humacyte or Palisade Bio?
Palisade Bio (PALI) is larger, with a market capitalization of $150.74M compared with $123.73M for Humacyte (HUMA).
Which stock has performed better over the past year, HUMA or PALI?
PALI returned -60.57% over the past 12 months, compared with -63.49% for HUMA (price return, excluding dividends). Past performance does not predict future results.
Are Humacyte and Palisade Bio in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.